References

1. Bendesky A, Sonabend AM. On Schleppfuss' path: the placebo response in

human evolution. Med Hypotheses. 2005;64(2):414-416.
2. Sonabend AM, Lesniak MS. Oligodendrogliomas: clinical significance of 1p and
19q chromosomal deletions. Expert Rev Neurother. 2005;5(6 Suppl):S25-32.
3. Cruz-Revilla C, Sonabend AM, Rosas G, et al. Intrahepatic DNA vaccination:
unexpected increased resistance against murine cysticercosis induced by non-
specific enhanced immunity. J Parasitol. 2006;92(3):655-657.
4. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with
CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with
experimental brain tumors. Glia. 2006;54(6):526-535.
5. Musleh W, Sonabend AM, Lesniak MS. Role of craniotomy in the management
of pituitary adenomas and sellar/parasellar tumors. Expert Rev Anticancer Ther.
2006;6 Suppl 9:S79-83.
6. Sonabend AM, Musleh W, Lesniak MS. Oncogenesis and mutagenesis of
pituitary tumors. Expert Rev Anticancer Ther. 2006;6 Suppl 9:S3-14.
7. Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Oncolytic adenoviral therapy for
glioblastoma multiforme. Neurosurg Focus. 2006;20(4):E19.
8. Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral
vectors for malignant glioma. Rev Med Virol. 2006;16(2):99-115.
9. Tyler MA, Ulasov IV, Borovjagin A, et al. Enhanced transduction of malignant
glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol
Cancer Ther. 2006;5(9):2408-2416.
10. Kushen MC, Sonabend AM, Lesniak MS. Current immunotherapeutic strategies
for central nervous system tumors. Surg Oncol Clin N Am. 2007;16(4):987-1004,
xii.
11. Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor
variant III: a novel strategy for the therapy of malignant glioma. Expert Rev
Anticancer Ther. 2007;7(12 Suppl):S45-50.
12. Sonabend AM, Ulasov IV, Lesniak MS. Emerging role of new transgenic mouse
models in glioma research. Expert Rev Anticancer Ther. 2007;7(12 Suppl):S7-13.
13. Sonabend AM, Ulasov IV, Lesniak MS. Gene therapy trials for the treatment of
high-grade gliomas. Gene Ther Mol Biol. 2007;11(A):79-92.
14. Ulasov IV, Rivera AA, Nettelbeck DM, et al. An oncolytic adenoviral vector
carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol.
2007;31(5):1177-1185.
15. Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin,
midkine and CXCR4 promoters for transcriptional targeting of glioma gene
therapy. Cancer Biol Ther. 2007;6(5):679-685.
16. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in
malignant glioma. Anticancer Res. 2008;28(2B):1143-1150.
17. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS.
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to
intracranial glioma. Stem Cells. 2008;26(3):831-841.
18. Sonabend AM, Velicu S, Ulasov IV, et al. A safety and efficacy study of local
delivery of interleukin-12 transgene by PPC polymer in a model of experimental
glioma. Anticancer Drugs. 2008;19(2):133-142.
19. Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Vector therapies for
malignant glioma: shifting the clinical paradigm. Expert Opin Drug Deliv.
2008;5(4):445-458.
20. Kranzler J, Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Stem cells as
delivery vehicles for oncolytic adenoviral virotherapy. Curr Gene Ther.
2009;9(5):389-395.
21. Sonabend AM, Ulasov IV, Han Y, et al. Biodistribution of an oncolytic
adenovirus after intracranial injection in permissive animals: a comparative study
of Syrian hamsters and cotton rats. Cancer Gene Ther. 2009;16(4):362-372.
22. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial
glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262-
278.
23. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS.
Combination of adenoviral virotherapy and temozolomide chemotherapy
eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Br J Cancer. 2009;100(7):1154-1164.
24. Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells:
the final frontier for glioma virotherapy. Stem Cell Rev. 2011;7(1):119-129.
25. Lei L, Sonabend AM, Guarnieri P, et al. Glioblastoma models reveal the
connection between adult glial progenitors and the proneural phenotype. PLoS
One. 2011;6(5):e20041.
26. Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer SA, Connolly ES,
Jr. Prevention of ventriculostomy-related infections with prophylactic antibiotics
and antibiotic-coated external ventricular drains: a systematic review.
Neurosurgery. 2011;68(4):996-1005.
27. Sonabend AM, Stuart RM, Yun J, et al. Prolonged intracerebral convection-
enhanced delivery of topotecan with a subcutaneously implantable infusion pump.
Neuro Oncol. 2011;13(8):886-893.
28. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic
hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem
cells to temozolomide therapy. Mol Med. 2011;17(1-2):103-112.
29. Goldstein H, Sonabend AM, Connolly ES, Jr. Chronic subdural hematomas:
perspective on current treatment paradigms. World Neurosurg. 2012;78(1-2):66-
68.
30. Sonabend AM, Ogden AT, Maier LM, et al. Medulloblasoma: challenges for
effective immunotherapy. J Neurooncol. 2012;108(1):1-10.
31. Yun J, Sonabend AM, Ulasov IV, et al. A novel adenoviral vector labeled with
superparamagnetic iron oxide nanoparticles for real-time tracking of viral
delivery. J Clin Neurosci. 2012;19(6):875-880.
32. Sonabend AM, Yun J, Lei L, et al. Murine cell line model of proneural glioma
for evaluation of anti-tumor therapies. J Neurooncol. 2013;112(3):375-382.
33. Baldock AL, Ahn S, Rockne R, et al. Patient-specific metrics of invasiveness
reveal significant prognostic benefit of resection in a predictable subset of
gliomas. PLoS One. 2014;9(10):e99057.
34. Baldock AL, Yagle K, Born DE, et al. Invasion and proliferation kinetics in
enhancing gliomas predict IDH1 mutation status. Neuro Oncol. 2014;16(6):779-
786.
35. Gill BJ, Pisapia DJ, Malone HR, et al. MRI-localized biopsies reveal subtype-
specific differences in molecular and cellular composition at the margins of
glioblastoma. Proc Natl Acad Sci U S A. 2014;111(34):12550-12555.
36. Sonabend AM, Bansal M, Guarnieri P, et al. The transcriptional regulatory
network of proneural glioma determines the genetic alterations selected during
tumor progression. Cancer Res. 2014;74(5):1440-1451.
37. Sonabend AM, Bruce JN. Management paradigms along a histologic spectrum of
pineal cell tumors. World Neurosurg. 2014;81(5-6):685-687.
38. Sonabend AM, Carminucci AS, Amendolara B, et al. Convection-enhanced
delivery of etoposide is effective against murine proneural glioblastoma. Neuro
Oncol. 2014;16(9):1210-1219.
39. Sonabend AM, Zacharia BE, Goldstein H, et al. Response. J Neurosurg.
2014;120(2):298-299.
40. Sonabend AM, Zacharia BE, Goldstein H, et al. The role for adjuvant
radiotherapy in the treatment of hemangiopericytoma: a Surveillance,
Epidemiology, and End Results analysis. J Neurosurg. 2014;120(2):300-308.
41. D'Amico RS, Cloney MB, Sonabend AM, et al. The Safety of Surgery in Elderly
Patients with Primary and Recurrent Glioblastoma. World Neurosurg.
2015;84(4):913-919.
42. Sonabend AM, McKhann GM. Boosting Dendritic Cell Vaccination for
Glioblastoma Using Tetanus Toxoid. Neurosurgery. 2015;77(2):N20-21.
43. Cloney M, D'Amico R, Lebovic J, et al. Frailty in Geriatric Glioblastoma
Patients: A Predictor of Operative Morbidity and Outcome. World Neurosurg.
2016;89:362-367.
44. Lieber BA, Appelboom G, Taylor BE, et al. Preoperative chemotherapy and
corticosteroids: independent predictors of cranial surgical-site infections. J
Neurosurg. 2016;125(1):187-195.
45. Sonabend AM, Bowden S, Bruce JN. Microsurgical resection of pineal region
tumors. J Neurooncol. 2016;130(2):351-366.
46. Sonabend AM, Zacharia BE, Cloney MB, et al. Defining Glioblastoma
Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study.
Neurosurgery. 2016.
47. Spence NZ, Faloba K, Sonabend AM, Bruce JN, Anastasian ZH. Venous air
embolus during scalp incision. J Clin Neurosci. 2016;28:170-171.
48. Cloney MB, Sonabend AM, Yun J, et al. The safety of resection for primary
central nervous system lymphoma: a single institution retrospective analysis. J
Neurooncol. 2017.
49. Chang PD, Malone HR, Bowden SG, et al. A Multiparametric Model for Mapping
Cellularity in Glioblastoma Using Radiographically Localized Biopsies. Am J
Neuroradiol. 2017.
50. Yun J, Iwamoto FM, Sonabend AM. Primary Central Nervous System
Lymphoma: A Critical Review of the Role of Surgery for Resection. Arch Cancer
Res. 2017.
51. Mehta AM, Sonabend AM, Bruce JN. Convection-Enhanced Delivery.
Neurotherapeutics. 2017 Apr;14(2):358-371.
52. Kinslow CJ, Rajpara RS, Wu CC et al. Invasiveness is associated with metastasis
and decreased survival in hemangiopericytoma of the central nervous system. J
Neurooncol. 2017 Apr 26